Details of the Drug Formulations

General Information of Drug (ID: DM5IXKQ)

• Drug Name: Vismodegib Drug Info
• Synonyms: 879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449

Indication

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Approved	[1]
Primitive neuroectodermal tumour medulloblastoma	2A00.11	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 24776445
  ChEBI ID: CHEBI:66903
  CAS Number: 879085-55-9
  TTD ID: D03EDQ
  VARIDT ID: DR00234
  INTEDE ID: DR1698
  ACDINA ID: D00730

Full List of Drug Formulations Containing This Drug

Vismodegib 150 mg capsule

Company	Formulation ID	FDA Description
Genentech	F22459	Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Povidone k30; Gelatin, unspecified; Microcrystalline cellulose; Sodium starch glycolate type a potato

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
• [2] A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.